Background: Over half of breast cancer patients discontinue their adjuvant hormone therapy, permanently or temporarily. We aimed to identify predictors of treatment restarting after discontinuation of adjuvant hormone therapy and to test the hypothesis that treatment restarting is associated with better breast cancer outcomes. Methods: We conducted a population-based cohort study by linking data from the Stockholm-Gotland Breast Cancer Register, the Swedish Prescribed Drug Register, and a self-reported questionnaire. We followed women diagnosed with breast cancer (Stockholm, Sweden, 2005 -2008 from their first prescription of tamoxifen or aromatase inhibitors through January 31, 2015, and categorized them as continuers (n ¼ 1 607), restarters (n ¼ 953), and nonrestarters (n ¼ 511) of adjuvant hormone therapy. All statistical tests were two-sided. Results: Factors that decrease the likelihood of treatment restarting included younger age (<50 years), higher Charlson Comorbidity Score (2), smaller tumor size (<20 mm), human epidermal growth factor receptor 2 negative, lymph node negative, family history of breast cancer negative, using hormone therapy, using symptom relieving drugs, and switching therapy between tamoxifen and aromatase inhibitors. Restarting adjuvant hormone therapy was statistically significantly associated with prolonged disease-free survival, with an adjusted hazard ratio of 0.61 (95% confidence interval ¼ 0.43 to 0.87, P ¼ .006) for restarters vs nonrestarters. Conclusions: Our study provides-for the first time to our knowledge-evidence that restarting adjuvant hormone therapy is associated with better breast cancer outcomes. Clinicians now have further evidence to encourage patients to restart their treatment after discontinuation of adjuvant hormone therapy.
Adjuvant hormone therapy has been reported to lower the risk of breast cancer mortality by 31% in women with estrogen receptor-positive tumors (1, 2) . However, discontinuation of adjuvant hormone therapy is common in breast cancer patients (3) (4) (5) . It has been reported that 31% to 73% of breast cancer patients discontinued their adjuvant hormone therapy during a five-year follow-up (6) (7) (8) (9) (10) (11) (12) (13) (14) . Therefore, over half of breast cancer patients may face the dilemma of whether or not to restart their treatment after discontinuation of adjuvant hormone therapy (14, 15) .
Discontinuation of adjuvant hormone therapy has been reported to increase the risk of recurrence and mortality in breast cancer patients (16, 17) . However, if and to what extent this increased risk can be reduced or eliminated by restarting adjuvant hormone therapy remains unknown. Furthermore, convincing patients to restart treatment could be a challenge (18) , and the identification of factors that prevent patients from restarting treatment could shed light on optimal interventions to improve adherence to adjuvant hormone therapy.
Using data from several Swedish registers and a populationbased cohort of breast cancer patients, we aimed to determine the prevalence and predictors of treatment restarting after discontinuation of adjuvant hormone therapy and to test the hypothesis that treatment restarting is associated with better breast cancer outcomes (as compared with nonrestarters).
Methods

Data Sources and Patients
This study was approved by the Regional Ethical Review Board in Stockholm, Sweden.
Swedish Registers
The Stockholm-Gotland Breast Cancer Register holds detailed information on all breast cancers diagnosed in the Stockholm/ Gotland health care region in Sweden since 1976 (14) . The Swedish Prescribed Drug Register holds detailed information on all dispensed prescriptions to the whole population of Sweden since July 1, 2005 , including dates of prescription and dispense, number of defined daily doses, and classification of drugs according to the Anatomic Therapeutic Chemical (ATC) Classification System (19) . The Swedish Prescribed Drug Register is reported to be complete, with less than 0.3% of entries having missing patient identity (19) .
Using the unique Swedish Personal Identification Number (20) , we linked the Stockholm-Gotland Breast Cancer Register to the Swedish Prescribed Drug Register. Through these linkages, we identified all women diagnosed with invasive breast cancer between 2005 and 2008 in Stockholm, Sweden, who initiated adjuvant hormone therapy with at least two prescriptions of tamoxifen (ATC codes L02BA01) or aromatase inhibitors (ATC codes L02BG; n ¼ 3299). We excluded 36 patients with distant metastasis at diagnosis, 34 patients with estrogen receptor-negative breast cancer, and 158 patients with fewer than 180 days of follow-up since treatment discontinuation (unable to define treatment restarting status based on our definition), leaving a total of 3071 patients for the final analysis.
Self-Reported Questionnaire
All women diagnosed with breast cancer between 2001 and 2008 in Stockholm-Gotland County, Sweden, were invited to donate blood and answer a web-based structured questionnaire between 2009 and 2010. In all, 1819 (59.2%) out of the 3071 breast cancer patients provided written informed consent and gave detailed information on lifestyle factors, reproductive history, and family history (14, (21) (22) (23) .
Discontinuation of Adjuvant Hormone Therapy and Treatment Restarting
Discontinuation of adjuvant hormone therapy was defined as having any interval between two consecutive dispenses exceeding 180 days during follow-up (14) . Because a three-month supply is the maximum that is allowed to be dispensed at each time in Sweden (24) , an interval of more than 180 days indicates that at least two dispenses have been missed, resulting in a shortage of the drug.
Treatment restarting was defined as subsequent filling of at least two prescriptions of tamoxifen or aromatase inhibitors after a discontinuation of adjuvant hormone therapy for at least 90 days.
Baseline Predictors of Treatment Restarting
Information on age at diagnosis, tumor size, lymph node status, progesterone receptor status, human epidermal growth factor receptor 2 (HER2) status, and type of surgery was retrieved from the Stockholm-Gotland Breast Cancer Register. Information on comorbidities used to calculate the Charlson Comorbidity Score (25) was retrieved from Swedish Patient Register (26) and Swedish Cancer Register (restricted to five years prior to breast cancer diagnosis) (27, 28) . Information on parity, heredity, cigarette smoking, and body mass index was retrieved from the self-reported questionnaire. Family history of breast cancer was defined as a self-reported positive BRCA mutation or a diagnosis of breast cancer in a first-degree relative (mother, sisters, or daughters). The use of hormone therapy was defined as filling at least one prescription of estrogen/progesterone (ATC codes G03C, G03D, G03F) for systematic use during one year before breast cancer diagnosis, excluding local use such as the patch and vaginal cream (14) .
Postdiagnosis Predictors of Treatment Restarting
Information on postdiagnosis use of symptom-relieving drugs was retrieved from the Swedish Prescribed Drug Register (19) . Prediscontinuation use of hypnotics/anxiolytics (ATC code N05B, N05C), antidepressants (ATC code N06A), analgesics (ATC code N02), and gastrointestinal drugs (ATC codes A02, A03, A04, A06, A07) was defined as filling at least one prescription of the corresponding drugs during the 60 days before treatment discontinuation. Postdiscontinuation use of hypnotics/anxiolytics, antidepressants, analgesics, and gastrointestinal drugs was defined as filling at least one prescription of the corresponding drugs during the 60 days after treatment discontinuation. Switching therapy was defined as switching from tamoxifen to aromatase inhibitors or vice versa before treatment discontinuation.
Outcome
Disease-free survival was defined as time to local recurrence, distant metastasis, contralateral breast cancer (>3 months after the primary breast cancer), or death from breast cancer. Information on local recurrence, distant metastasis, and contralateral breast cancer were retrieved from the StockholmGotland Breast Cancer Register (29) . Cause of death was retrieved from the Cause of Death Register (30) .
Follow-up
Follow-up to Define Treatment Discontinuation Patients were followed from their first prescription of tamoxifen or aromatase inhibitors until death, local recurrence, distant metastasis, contralateral cancer, emigration, end of study period (January 31, 2015), or completion of five-year follow-up, whichever came first, to define treatment discontinuation (14) . Information on date of emigration was retrieved from the Swedish Emigration Register. Date of treatment discontinuation was defined as the date on which the last prescription was filled plus the days of supply corresponding to that last prescription. Time to treatment discontinuation was defined as the time interval between the date of treatment initiation and the date of treatment discontinuation.
ARTICLE
Follow-up to Define Treatment Restarting Among discontinuers, patients were followed from their date of treatment discontinuation until any date indicated above to define treatment restarting. Date of treatment restarting was defined as the date on which the first prescription after treatment discontinuation was filled.
Follow-up to Define Disease-Free Survival Among discontinuers, patients were followed from the end of the first year following treatment discontinuation until death, emigration, or end of study period (January 31, 2015), whichever came first, to define disease-free survival. Specifically, we first categorized breast cancer patients into restarters and nonrestarters according to whether or not they restarted treatment during the one-year follow-up after treatment discontinuation. We then compared their potential difference in disease-free survival during the following years. We chose the cutoff of one year because 1) among patients who subsequently restarted their treatment, 97.9% restarted within the first year; and 2) breast cancer events that occurred within the first year (since treatment discontinuation) may not directly be related to the status of treatment restarting.
Statistical Analysis
To identify predictors of treatment restarting after discontinuation of adjuvant hormone therapy, univariable Cox regression was first used to explore crude associations. Only variables with a P value of less than .15 in the univariate analysis were then included in the multivariable Cox model. The proportionalhazards assumption was tested using the Schoenfeld residual test, and no major model violation was observed.
To investigate the impact of treatment restarting on diseasefree survival, we first calculated a propensity score with logistic regression to estimate the probability of treatment restarting for each patient. We then conducted a Kaplan-Meier analysis and Cox regression analysis to investigate the difference in disease-free survival among discontinuers of adjuvant hormone therapy, comparing restarters with nonrestarters, after adjusting for the propensity score as a continuous variable.
Sensitivity analyses were conducted to assess the robustness of our findings. First, we repeated our analysis after further excluding patients who discontinued, restarted, and then discontinued again during the follow-up (n ¼ 453). Second, we reanalyzed our data using mixture cure model (31) because the rate of treatment restarting plateaus one year after treatment discontinuation, indicating that a proportion of patients never experience the events (treatment restarting) during longer follow-up. Third, we repeated our analysis using multivariable Cox regression (rather than adjusting for propensity score) to investigate the impact of treatment restarting on disease-free survival. Finally, we redefined treatment restarting based on nine-month and 15-month (instead of one-year) follow-up to investigate the impact of varying time windows in defining treatment restarting on the subsequent disease-free survival.
All statistical analyses were two-sided and were performed using SAS version 9.4 (SAS Institute, Cary, NC) or Stata version 13.0 (Stata Corporation, College Station, TX). Statistical significance was determined at a P value of less than .05. Figure 1 presents the flow chart of the study participants. Of the 3071 patients included in the final analysis, 1607 (52.3%) were defined as continuers, 953 (31.0%) as restarters, and 511 (16.7%) as nonrestarters. Most of the women included in our study were age 50 years or older, with Charlson Comorbidity Score of 0, had a tumor size smaller than 20 mm, and had a negative lymph node at the time of breast cancer diagnosis (Supplementary  Table 1 , available online).
Results
Patient Characteristics
Rate of Treatment Restarting
The rate of treatment restarting increased dramatically during the first year since treatment discontinuation and remained constant afterward (Supplementary Figure 1, Table 1 presents the baseline predictors of treatment restarting after discontinuation of adjuvant hormone therapy. Patients who were younger (age < 50 years), had a Charlson Comorbidity Score of 2 or higher, had no family history of breast cancer, and had used hormone therapy one year before breast cancer diagnosis were less likely to restart their treatment. Furthermore, patients diagnosed with a tumor of good expected prognosis (HER2 negative, lymph node negative, and tumor size < 20 mm) were also less likely to restart their treatment after discontinuation of adjuvant hormone therapy. Table 2 presents the postdiagnosis predictors of treatment restarting. Patients who switched their therapy from tamoxifen to aromatase inhibitors or vice versa, patients who discontinued their treatment within year 1 or after year 3 since treatment initiation, and patients who used symptom-relieving drugs before or after treatment discontinuation were less likely to restart their treatment after discontinuation of adjuvant hormone therapy.
Baseline Predictors of Treatment Restarting
Postdiagnosis Predictors of Treatment Restarting
Disease-Free Survival
Based on the predictors identified above, a propensity score was calculated using logistic regression to estimate the probability of treatment restarting for each patient (Supplementary Table 2 , available online). Figure 2 presents the propensity score-adjusted Kaplan-Meier estimate of disease-free survival among discontinuers of adjuvant hormone therapy, comparing restarters with nonrestarters. Specifically, the adjusted eight-year disease-free survival was 89.8% (95% CI ¼ 86.7% to 92.2%) for restarters and 82.0% (95% CI ¼ 76.6% to 86.3%) for nonrestarters. Cox regression analysis showed that treatment restarting was statistically significantly associated with prolonged disease-free survival, with an adjusted hazard ratio of 0.61 (95% CI ¼ 0.43 to 0.87, P ¼ .006) for restarters compared with nonrestarters, after adjusting for propensity score.
Sensitivity Analysis
Repeating analyses after further excluding patients that discontinued, restarted, and then discontinued again during the follow-up yielded, in general, comparable results both regarding disease-free survival and predictors of treatment restarting. Repeating the analysis using mixture cure models provided consistent results regarding predictors of occurrence of treatment restarting (Supplementary Tables 3 and 4, available 
Discussion
Our study provides-for the first time-evidence that restarting adjuvant hormone therapy was associated with better breast cancer outcomes. However, one in three breast cancer patients never restarted their treatment after discontinuation of adjuvant hormone therapy. Patients were less likely to restart therapy if they were younger at diagnosis, had comorbidities, had no family history of breast cancer, and had used hormone therapy. Switching adjuvant therapy and use of symptom-relieving drugs were associated with treatment nonrestarting. Interestingly, tumor characteristics were also associated with the likelihood of restarting-patients diagnosed with a tumor of good expected prognosis (<2 cm tumor size, node negative, and HER2 negative) were less likely to restart.
Of women who restarted their treatment, 84.3% restarted within the first six months following discontinuation of adjuvant hormone therapy. This result highlights the importance of immediate intervention, suggesting that patients may be more likely to be persuaded to restart their treatment if the intervention can be conducted soon after their discontinuation.
Treatment nonrestarting was more likely to appear if treatment discontinuation occurred within the first year or after year 3 since treatment initiation, indicating that early and late discontinuation may have different causes (14, 32) . The underlying mechanisms for this observation remain unknown, and we cannot rule out the possibility that the lower rate of treatment restarting observed among those who discontinued in year 5 was, at least in part, due to the short period of follow-up (2 subsequent prescriptions are needed to define treatment restarting).
Breast cancer patients with a good expected prognosis were less likely to restart their treatment after discontinuation of adjuvant hormone therapy. This result is understandable if these patients believe that a small tumor does little harm once removed. Such belief might in turn influence the risk-benefit balance assessment of the patients regarding adjuvant hormone therapy.
Treatment-related side effects may serve as an important barrier to treatment restarting among discontinuers. We show that the greater number of prescribed symptom-relieving drugs, the higher the risk of treatment nonrestarting. Because medications for pain, depression, gastrointestinal disorders, and sleep disorders are indicators of treatment-related side effects, this result suggests that patients who discontinued their treatment because of intolerable side effects may be less likely to restart their treatment, underscoring again the importance of side effect management among users of adjuvant hormone therapy (8) .
Younger age at diagnosis, higher Charlson Comorbidity Score, and hormone therapy can predict both early discontinuation and nonrestarting after discontinuation of adjuvant hormone therapy (14, 33) . However, family history of breast cancer did not predict early discontinuation in our previous study (14) , but it appears to predict treatment restarting in the present study. Therefore, although discontinuation and nonrestarting after discontinuation of adjuvant hormone therapy may indeed share common risk factors, they are, in essence, two different research questions and need to be investigated separately. 
ARTICLE
For the first time, we tested and supported the hypothesis that restarting adjuvant hormone therapy is to the benefit of the patients, with prolonged disease-free survival observed among restarters as compared with nonrestarters. This finding is important because clinicians now have further evidence to encourage discontinuers to restart their adjuvant hormone therapy. Furthermore, given that commonness of discontinuation of adjuvant hormone therapy in breast cancer patients (9, 11, 14, 15) , interventions to promote treatment restarting may benefit a large proportion of breast cancer patients. Thus, treatment restarting may serve as an additional but currently neglected target for interventions to improve breast cancer outcomes.
Medication consumption is a complex behavior that requires at least three steps or studies in order to be fully understood. First, in a previous study, we have shown that over half of *A higher hazard ratio indicates a higher likelihood to restart treatment after discontinuation of adjuvant hormone therapy. CI ¼ confidence interval. †Adjusting for age, Charlson Comorbidity Score, hormone therapy, human epidermal growth factor receptor 2 status, tumor size, lymph node involvement, and family history of breast cancer (yes, no, unknown, and no response to questionnaire survey). ‡Prediscontinuation use of hypnotics/anxiolytics, antidepressants, analgesics, and gastrointestinal drugs was defined as filling at least one prescription of the corresponding drugs during the 60 days before treatment discontinuation. §Postdiscontinuation use of hypnotics/anxiolytics, antidepressants, analgesics, and gastrointestinal drugs was defined as filling at least one prescription of the corresponding drugs during the 60 days after treatment discontinuation.
breast cancer patients discontinued their adjuvant hormone therapy during a five-year follow-up (14) . Second, in the present study, we show that of the discontinuers, two in three subsequently restarted their treatment. Therefore, many patients often described as "discontinuers" might more accurately be described as "nonadherent users" or "temporary discontinuers." Third, among women who restarted their treatment after discontinuation of adjuvant hormone therapy in our study, 47.5% discontinued their treatment again after treatment restarting. This repeated discontinuation is another challenging issue that should be investigated in future studies. Our study has certain limitations. First, prescription refills were used to define discontinuation and restarting of adjuvant hormone therapy. However, prescription refill does not necessarily mean that a patient is taking the medication as prescribed. Second, only 59.2% of the study participants responded to our questionnaire survey. Therefore, we cannot rule out the possibility of nonresponse bias for our questionnaire-based results. Third, no data on reasons for discontinuation were collected in our registers or in our questionnaire survey, thus preventing comparisons between those who discontinued because of treatment-related symptoms and those who discontinued because of other reasons. Fourth, this is an observational study and we cannot rule out the possibility that the difference in disease-free survival observed between restarters and nonrestarters may be partially due to unmeasured factors. Finally, our study was conducted in a country with a unified health care system that is fully covered through taxes. The generalizability of our findings to other countries with different health care systems could be questioned.
In conclusion, this study represents the first report investigating treatment restarting after discontinuation of adjuvant hormone therapy in breast cancer patients. We found that treatment restarting is associated with prolonged disease-free survival among discontinuers of adjuvant hormone therapy. Clinicians now have further evidence to encourage breast cancer patients to restart their treatment after discontinuation of adjuvant hormone therapy. 
Notes
The study funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication. Years since treatment discontinuation Restarters Nonrestarters Figure 2 . Adjusted Kaplan-Meier estimate of disease-free survival among discontinuers of adjuvant hormone therapy, restarters vs nonrestarters. Treatment restarting status was defined based on one-year follow-up (since treatment discontinuation). Patients who restarted their treatment after one year of follow-up (n ¼ 20) and patients who experienced any disease-free survival event (n ¼ 41) within the first year since treatment discontinuation were excluded from this analysis. The curve was adjusted to the mean of the propensity score (to treatment restarting). The P value was calculated using a two-sided Wald test.
